Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert I Nicholson

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
Breast Cancer Research and Treatment|March 17, 2009
Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistanceNicholas B P Thomas, Iain R Hutcheson, Lee Campbell, et al.
Clinical Breast Cancer|December 3, 2014
A good drug made better: the fulvestrant dose-response storyJohn F R Robertson, Justin Lindemann, Sally Garnett, et al.
Cancer Research|January 10, 2002
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breastKai C Chan, W Fiona Knox, Julia M Gee, et al.
International Journal of Cancer|July 17, 2015
Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsiesAmit Agrawal, John F R Robertson, Kwok L Cheung, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2008
Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significanceHany Onsy Habashy, Desmond G Powe, Emad A Rakha, et al.
Breast Cancer Research and Treatment|October 9, 2003
Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cellsIain R Hutcheson, Janice M Knowlden, Tracie-Ann Madden, et al.
Breast Cancer Research : BCR|September 24, 2011
erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell linesJanice M Knowlden, Julia M W Gee, Denise Barrow, et al.
International Journal of Cancer|January 9, 2004
Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancerNeil K Rushmere, Janice M Knowlden, Julia M W Gee, et al.
BMC Cancer|October 9, 2012
Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronanStephen Hiscox, Bedanta Baruha, Chris Smith, et al.
Molecular Medicine (Cambridge, Mass.)|August 4, 2007
The emerging role of the LIV-1 subfamily of zinc transporters in breast cancerKathryn M Taylor, Helen E Morgan, Kathryn Smart, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Breast Cancer Research and Treatment|March 17, 2009
Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistanceNicholas B P Thomas, Iain R Hutcheson, Lee Campbell, et al.
Clinical Breast Cancer|December 3, 2014
A good drug made better: the fulvestrant dose-response storyJohn F R Robertson, Justin Lindemann, Sally Garnett, et al.
Cancer Research|January 10, 2002
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breastKai C Chan, W Fiona Knox, Julia M Gee, et al.
International Journal of Cancer|July 17, 2015
Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsiesAmit Agrawal, John F R Robertson, Kwok L Cheung, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2008
Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significanceHany Onsy Habashy, Desmond G Powe, Emad A Rakha, et al.
Breast Cancer Research and Treatment|October 9, 2003
Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cellsIain R Hutcheson, Janice M Knowlden, Tracie-Ann Madden, et al.
Breast Cancer Research : BCR|September 24, 2011
erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell linesJanice M Knowlden, Julia M W Gee, Denise Barrow, et al.
International Journal of Cancer|January 9, 2004
Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancerNeil K Rushmere, Janice M Knowlden, Julia M W Gee, et al.
BMC Cancer|October 9, 2012
Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronanStephen Hiscox, Bedanta Baruha, Chris Smith, et al.
Molecular Medicine (Cambridge, Mass.)|August 4, 2007
The emerging role of the LIV-1 subfamily of zinc transporters in breast cancerKathryn M Taylor, Helen E Morgan, Kathryn Smart, et al.
Pageof 8